CCR1 and neoplasm: Tamihiro's future research will focus on the identification and characterization of AM-like TAMs in advanced human lung adenocarcinoma, including pre-clinical evaluation of co-targeting of AM-like TAMs (with statins/CCR1 inhibitors) and the tumour immune microenvironment (with immune checkpoint blockers) for human lung adenocarcinoma, using a patient-derived explant culture platform.